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Pedro Romero-Aroca6 , Rafael Simó7,8,9 , Didac Mauricio2,9,10,11 ,
Manel Mata-Cases2,9,12 , Esmeralda Castelblanco2,13 ,
Xavier Mundet-Tuduri2,4* and Josep Franch-Nadal2,9,14
1

Primary Health Care Center Dr. Jordi Nadal i Fàbregas (Salt), Gerència d’Atenció Primària, Institut
Català de la Salut, Girona, Spain, 2 Diabetis des de l’Atenció Primária (DAP)-Cat Group, Unitat
de Suport a la Recerca Barcelona, Fundació Institut Universitari per a la Recerca a l’Atenció Primària
de Salut Jordi Gol i Gurina (IDIAPJGOL), Barcelona, Spain, 3 Fundació Institut Universitari per a la
Recerca a l’Atenció Primària de Salut Jordi Gol i Gorina (IDIAPJGOL), Barcelona, Spain,
4
Departament of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain, 5 Hospital de la
Santa Creu i Sant Pau, Barcelona, Spain, 6 Ophthalmology Service, University Hospital Sant Joan,
Institut de Investigacio Sanitaria Pere Virgili (IISPV), University of Rovira and Virgili, Reus, Spain,
7
Diabetes and Metabolism Research Unit, Department of Endocrinology, Vall d’Hebron University
Hospital, Vall d’Hebron Research Institute, Barcelona, Spain, 8 Department of Medicine, Faculty
of Medicine, Autonomous University of Barcelona, Barcelona, Spain, 9 Centro de Investigación
Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Barcelona,
Spain, 10 Department of Endocrinology and Nutrition, Hospital de la Santa Creu i Sant Pau,
Barcelona, Spain, 11 Departament of Medicine, University of Vic—Central University of Catalonia, Vic,
Spain, 12 Centre d’Atenció Primària La Mina, Gerència d’Àmbit d’Atenció Primària de Barcelona,
Institut Català de la Salut, Barcelona, Spain, 13 Division of Endocrinology, Metabolism and Lipid
Research, John T. Milliken Department of Medicine, School of Medicine, Washington University
in St. Louis, St. Louis, MO, United States, 14 Primary Health Care Center Raval Sud, Gerència d’Àmbit
d’Atenció Primaria, Institut Català de la Salut, Barcelona, Spain

This study aimed to evaluate the predictive value of diabetic retinopathy
(DR) and its stages with the incidence of major cardiovascular events and
all-cause mortality in type 2 diabetes mellitus (T2DM) persons in our large
primary healthcare database from Catalonia (Spain). A retrospective cohort
study with pseudo-anonymized routinely collected health data from SIDIAP
was conducted from 2008 to 2016. We calculated incidence rates of
major cardiovascular events [coronary heart disease (CHD), stroke, or both—
macrovascular events] and all-cause mortality for subjects with and without
DR and for different stages of DR. The proportional hazards regression analysis
was done to assess the probability of occurrence between DR and the study
events. About 22,402 T2DM subjects with DR were identified in the database
and 196,983 subjects without DR. During the follow-up period among the
subjects with DR, we observed the highest incidence of all-cause mortally. In
the second place were the macrovascular events among the subjects with DR.
In the multivariable analysis, fully adjusted for DR, sex, age, body mass index
(BMI), tobacco, duration of T2DM, an antiplatelet or antihypertensive drug, and
HbA1c, we observed that subjects with any stage of DR had higher risks for all
of the study events, except for stroke. We observed the highest probability
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of all-cause death events (adjusted hazard ratios, AHRs: 1.34, 95% CI: 1.28;
1.41). In conclusion, our results show that DR is related to CHD, macrovascular
events, and all-cause mortality among persons with T2DM.
KEYWORDS

diabetic retinopathy, macrovascular complication, primary healthcare, real word data
analyses, mortality

Introduction

risk of mortality from all causes compared to subjects with
diabetes who do not have retinopathy (RR: 2.33, 95% CI: 1.92;
2.81) (30–32).
So far, to the best of our knowledge, there is a lack of studies
evaluating the relation between DR and major cardiovascular
events from primary healthcare settings. In this study, we aimed
to evaluate the predictive value of DR, its severity with the
incidence of major cardiovascular events [coronary heart disease
(CHD) and stroke], and all-cause mortality in subjects with
T2DM in a Mediterranean region.

Diabetes mellitus has become one of the major public
health challenges globally, both in developed and developing
countries (1). The increasing prevalence of diabetes worldwide is
caused by a complex interplay of socioeconomic, demographic,
environmental, and genetic factors. The International Diabetes
Federation (IDF) estimates that 10.5% of adults between 20 and
79 years have diabetes, equating to 537 million people (2). The
IDF also estimates that 643 million adults will live with diabetes
in 2030 (11.3% of the population), and the number will reach
783 million (12.2%) by 2045.
The main burden of diabetes results from its complications.
Diabetic retinopathy (DR) is a microvascular and
neurodegenerative complication whose prevalence increases
with disease duration and causes a high risk of severe visual
impairment and blindness (3, 4). According to recently
published studies, there is considerable variability in the
prevalence of DR. The meta-analysis of Yau et al. reports that
one in every three subjects with diabetes will present some
degree of DR (5) compared to 27% in the last review and
the analysis of the IDF from the studies published in recent
years (6).
Diabetes can cause numerous complications that weaken
health, lower quality of life, and cause early death. People
with diabetes are two to three times more likely to develop
cardiovascular disease, and the risk of death doubles compared
to people without diabetes (7).
The consequences of late detection of DR go beyond
the resulting suboptimal visual acuity (8, 9). We have
extensive evidence that associates DR with other micro- and
macrovascular complications of diabetes. Recently, it was
reported that DR is associated with subclinical atherosclerosis
(10–14), macrovascular comorbidities such as coronary disease
(15–20) and cerebrovascular accident (21–26). Of interest,
some studies have reported an association between cognitive
impairment and the incidence of dementia [risk ratio (RR),
1.3; 95% confidence interval (CI), 1.27–1.58] (27, 28), and the
relation between DR and neurodegeneration diseases such as
Parkinson’s disease has been proposed but remains unclear (29).
In addition, a recent meta-analysis with observational studies
found that subjects with diabetes who have DR have an increased
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Materials and methods
The study included a retrospective cohort of subjects with
T2DM from the SIDIAP database (Sistema de Información
para el desarrollo de la Investigación en Atención Primaria).
The SIDIAP database routinely collects pseudo-anonymized
health data from users who attend the primary healthcare
centers of the Catalonian Health Institute (Institut Català de
la Salut, ICS). The ICS is the primary healthcare provider
in Catalonia (Spain), covering about 80% (5,564,292 persons)
of the Catalonian population. The SIDIAP database contains
comprehensive patient data, such as visits with healthcare
professionals, diagnoses, demographic information, clinical
variables, laboratory test results, prescriptions, referrals to
specialists and hospitals, and medication obtained from
pharmacies. For this analysis, data were extracted covering
a 10-year period. The inclusion period was defined from 1
January 2008 to 31 December 2012. The follow-up period was
until the data extraction end date (31 December 2017) or a
discontinuation event (death or any other database dropout).

Participants
All subjects aged between 30 and 89 years with a diagnosis
of T2DM, defined as the presence of International Classification
of Diseases, 10th Revision (ICD-10) diagnostic codes: E11, E14
(and their subcodes), and screening for fundus photography
(to determine the presence of DR), were included in the
analysis. We excluded those subjects with other types of
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Statistical analysis

diabetes (type 1 diabetes, gestational diabetes, secondary, or
other), without diagnostic codes for T2DM, subjects with
cardiovascular events, and/or absence of fundus photography.
The eligible participants were followed up for at least 5 years or
until the discontinuation event.

A descriptive statistical analysis was carried out,
summarizing the quantitative parameters with the mean
and its standard deviation (SD), median or interquartile range,
and the qualitative variables with frequency and percentage.
We used an opportunistic sampling technique to capture all
persons meeting the study inclusion criteria. To assess the
association of the main study events considering the time of
follow-up, a time-to-event complete case analysis (CCA) was
performed, adjusting Cox proportional hazards models (34).
Unadjusted hazard ratios (UnAHRs) and adjusted hazard ratios
(AHRs), 95% CI, and p-value were estimated and summarized.
We used Kaplan–Meier survival curves to graphically visualize
the cumulative incidence for study events during the follow-up
period in each group. Different study events were fully adjusted
considering potentially confounding clinical variables such as
DR, sex, age, BMI, tobacco, duration of T2DM, antiplatelet
or antihypertensive drug treatment, and HbA1c. Additionally,
we performed a model adding lipid-lowering and antidiabetic
drugs to the previous model. To treat missing data, a multiple
imputation analysis (MICE) was performed with the statistical
package (35) using ten replicates and five iterations. The
CCA and MICE analyses were compared in a sensitivity
analysis, adjusting the models for different variables (Model
1: unadjusted; Model 2: adjusted for age and sex; Model 3:
adjusted for sex, smoking, antiplatelet or antihypertensive
drug treatment, and BMI; Model 4: fully adjusted). P-values
less than 0.05 were considered statistically significant without
using the correction for multiple comparisons for the multiple
events analyzed. We used the cox.zph function in the survival
package (R statistical software) to check the proportional
hazards assumption of Cox models (34). Statistical analysis was
performed with R statistical software, version 3.6.1.1

Variables
For all the included subjects, the presence or absence
of DR was assessed using reports pertaining to digital 45◦
color fundus images. Two photographs were taken for
each eye, the macula-centered and between the macula and
the optic nerve. We only included fundus photography
from patients screened at primary healthcare centers.
DR was classified into different stages according to the
Early Treatment Diabetic Retinopathy Study (ETDRS)
classification (33) as no apparent retinopathy (NDR), mild
non-proliferative retinopathy (NPDR), moderate NPDR,
severe NPDR, proliferative diabetic retinopathy (PDR), and
diabetic macular edema (DME). The DR diagnosis was
taken from the worst-affected eye, and from the most recent
photograph in case there was more than one screening during
the inclusion period. Also, at inclusion, we collected sociodemographic variables (age, gender), toxic habits (current
tobacco use), and clinical variables related to diabetes [age
at diagnosis of diabetes, diabetes duration, and glycated
hemoglobin levels (HbA1c)]. Data on cardiovascular risk
factors [body mass index (BMI), blood lipids, total cholesterol,
low-density lipoprotein (LDL) cholesterol, high-density
lipoprotein (HDL) cholesterol, non-HDL cholesterol, blood
pressure, pulse pressure] were collected. Additional data
were gathered on medication. Obesity was defined as a
BMI ≥ 30 kg/m2 . The estimated glomerular filtration rate
(eGFR) was calculated according to the CKD Epidemiology
Collaboration (CKD-EPI) equation. Chronic kidney disease
(CKD) was defined as an estimated glomerular filtration rate
(eGFR) < 60 ml/min/1.73 m2 calculated using the CKD-EPI
equation and/or a ratio of albumin/creatinine (CAC) in
urine ≥ 30 mg/g.
During the follow-up period, we collected data on
mortality by any cause and by severe cardiovascular events
such as stroke (defined by ICD-10 codes and subcodes for
“cerebral infarctions” and/or “transient cerebral ischemic
attacks and related syndromes”) or CHD defined by
ICD-10 codes and subcodes for “angina pectoris” and/or
“acute myocardial infarction and/or subsequent myocardial
infarction” and/or “certain current complications following
acute myocardial infarction” and/or “chronic ischemic heart
disease.” Additionally, we created a composite event as a
combination of stroke and/or CHD, named as “macrovascular
events.” The definition of the study variables and codes are
summarized in Supplementary Table 1.
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Institutional review board statement
This study was approved by the Institutional Review Board
(or Ethics Committee) of IDIAP Jordi Gol i Gurina Foundation
(protocol code P13/028 and date of approval 03/04/2013).

Results
At the end of the inclusion period, 219,385 (86.5%) subjects
met the study inclusion criteria and were included in the
analysis. We identified 22,402 (10.2%) persons with any stage
DR. Figure 1 shows the study flow diagram. The mean age
(SD) of the subjects was 64.6 (± 11.6) years; the cohort
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FIGURE 1

Study flow chart.

higher proportion (28.3%) of subjects with LDL < 100 mg/dl
and higher mean HDL (HDL cholesterol). Subjects with DR
had a poorer renal profile than subjects without DR (eGFR,
70.9 (22.4) ml/min/1.73 m2 vs. 78.8 (19.7) ml/min/1.73 m2 ,
respectively). The proportions of subjects (32.4%) with
eGFR < 60 ml/min/1.73 m2 were higher than those without
DR. We observed 1.6 times higher CKD prevalence among
the subjects with DR than the subjects without DR. Regarding
good glycemic control (HbA1c < 7%), statistically significant

contained a slightly higher proportion of men than women
(55.7%) (Table 1).
Compared to those with normal fundus photography,
subjects who had DR (any stage) were older and had 1.6
times longer diabetes duration. Moreover, the DR group had
a smaller proportion of smokers and a higher proportion
(53.4%) of subjects with BMI < 30 kg/m2 . Furthermore, the
lipid profile was better in the DR group, with lower total
cholesterol, triglycerides, and LDL cholesterol levels, and a
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shortest time until the event was observed among the subjects
with CHD and DR.
In the bivariate analysis, we observed statistically significant,
unadjusted hazard ratios for all of the events, with the risk for the
study events being higher among the subjects with DR. When
stratified for the stage of DR, the same tendency was observed.
The highest risk for the study events was observed among the
subjects with proliferative DR. We did not observe statistically
significant HRs among the persons with DME and stroke events.
In the multivariable CCA, fully adjusted for DR, sex,
age, BMI, tobacco use, duration of T2DM, an antiplatelet or
antihypertensive drug, and HbA1c, we observed that subjects
with any stage of DR had higher risks for all of the study events.

differences were observed among the groups, in favor of subjects
without DR (61.3%) compared with subjects with DR (42.0%).

Association between diabetic
retinopathy and study events
Table 2 shows the epidemiology for different study events
for both subjects with or without DR. During the followup period among the subjects with DR, mortality (all cause)
was the most common event, followed by macrovascular
events, CHD, and then stroke. The same pattern was observed
among persons without DR, but with a lower incidence. The
TABLE 1 Clinical characteristics of the subjects at inclusion.

Male sex (%)

All N = 219,385

Without diabetic
retinopathy N = 196,983

With diabetic
retinopathy N = 22,402
12,296 (54.9)*

122,280 (55.7)

109,984 (55.8)*

Age (years), mean (SD)

64.6 (11.6)

64.4 (11.5)*

67.0 (11.6)*

Current tobacco use (%)

58,602 (26.0)

52,839 (28.1)*

5,763 (26.9)*

Diabetes duration (years)

5.18 (5.27)

4.84 (4.95)*

8.10 (6.81)*

BMI (kg/m2 )

30.6 (5.22)

30.7 (5.20)*

30.2 (5.33)*

SBP (mmHg)

134 (14.8)

134 (14.5)*

137 (16.3)*

DBP (mmHg)

77.1 (9.59)

77.3 (9.51)*

76.0 (10.2)*

Heart rate (beat/min)

76.5 (12.3)

76.4 (12.2)*

77.4 (12.4)*

HbA1c (%)

7.18 (1.53)

7.12 (1.49)*

7.76 (1.75)*

Total cholesterol (mg/dL)

198 (40.3)

198 (40.1)*

192 (41.5)*

HDL cholesterol (mg/dL)

49.0 (12.8)

49.0 (12.8)*

49.5 (13.4)*

LDL cholesterol (mg/dL)

117 (33.8)

118 (33.7)*

112 (34.4)*

Triglycerides (mg/dL)

168 (122)

169 (123)*

160 (112)*

GFR (CKD-EPI; ml/min/1.73 m2 )

78.0 (20.1)

78.8 (19.7)*

70.9 (22.4)*

Albumin-to-creatinine ratio

32.9 (131)

28.9 (114)*

67.5 (226)*

Clinical variables, mean (SD)

Laboratory variables, mean (SD)

Comorbidities (%)
Dyslipidemia

104,442 (47.6)

93,347 (47.4)*

11,095 (49.5)*

Hypertension

132,756 (60.5)

117,830 (59.8)*

14,926 (66.6)*

CKD

31,584 (14.4)

26,623 (13.5)*

4,961 (22.1)*
14,824 (66.2)*

Concomitant treatment (%)
Antihypertensive drugs

131,967 (60.2)

117,143 (59.5)*

Antiplatelet drugs

52,396 (23.9)

44,581 (22.6)*

7,815 (34.9)*

Antidiabetics drugs

160,166 (73.0)

141,309 (71.9)*

18,857 (84.2)*

Lipid-lowering drugs

103,059 (47.0)

92,143 (46.8)*

10,916 (48.7)*

BMI, body mass index; CKD, chronic kidney disease; GFR, glomerular filtration rate; HbA1c, glycosylate hemoglobin; SD, standard deviation. *p < 0.001.

TABLE 2 The overall incidence for the study events between both groups.

Events

Groups of
subjects

Patients/year

Event-free survival time
(median in years)

Events
(number)

Event rate (1,000
patients/year)

Mortality

No DR

1017964.6

4.950

17,527

17.2

DR

112524.5

4.750

3,364

29.9

No DR

998687.0

4.846

6,360

6.3

DR

109527.5

4.586

1,058

9.7

No DR

1006859.7

4.893

3,637

3.6

DR

110843.5

4.652

563

5.1

No DR

988167.7

4.786

9,758

9.9

DR

107933.7

4.498

1,584

14.7

CHD
Stroke
Macrovascular

CHD, coronary heart disease; stroke, macrovascular: CHD and/or stroke; event rate, incidence per 1,000 person-year.
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cardiovascular events at inclusion, during the follow-up of
7.8 years, the authors observed that the presence of DR was
associated with the occurrence of CHD events (HR: 2.07,
95% CI: 1.38; 3.11) and fatal CHD (HR: 3.35, 95% CI:
1.40; 8.01) (16). Compared with the results observed in our
study, during the follow-up over an average of 4.8 years, we
observed lower but statistically significant adjusted risks for
CHD (HR:1.27, 95% CI: 1.16; 1.39). In a recently reported
systematic review and meta-analysis of cohort studies, including
17,611 patients without a previous history of CV disease
at baseline, DR was associated with an increased risk of
CV disease (relative risk (RR): 2.42, 95% CI: 1.77; 3.31) in
diabetes (17). This risk was especially elevated among the
T1DM persons (RR: 3.59, 95% CI: 1.79; 7.20) compared with
T2DM persons (RR: 1.81, 95% CI: 1.47; 2.23) (17). Regarding
the severity of DR, only a few studies have evaluated the
association between the stage of DR and CV events. The studies
done by Gimeno-Orna et al. and Targher et al. reported an
increased risk between NPDR and RDP and the incidence
of non-fatal or fatal cardiovascular events, independently of
other known cardiovascular risk factors (HR:1.71, 95% CI:
1.1; 2.66 and HR: 2, 95% CI: 1.1; 3.56, respectively) (18,
19). Additionally, the Japan Diabetes Complications Study
(JDCS) that included 2,033 subjects with T2DM with an 8year follow-up period found an increased risk for CHD even
during the initial stages of DR (mild-to-moderate NPDR)
after adjusting for traditional CV risk factors (HR:1.69,
95% CI: 1.17; 2.97) (20). Our study observed a similar
tendency but with a lower HR for NPDR and CHD in a
fully adjusted model.
Evidence suggests that subjects with diabetes and DR
seem to be at a high risk of ischemic stroke, with a
meta-analysis that included 19 observational cohort studies
of 81,452 diabetic patients reporting that the presence of

The probability of an event occurring was highest for all-cause
death (AHR: 1.34, 95% CI: 1.28; 1.41) and lowest for stroke
(AHR: 1.09, 95% CI: 0.97; 1.24). Similar results were observed
when adding the lipid-lowering and antidiabetic drugs to the
additional model. The Kaplan–Meier survival curves for study
events are shown in Figure 2, and the results for the unadjusted
and adjusted HR are summarized in Table 3.

Sensitivity analysis
Figure 3 and Supplementary Table 2 show the HR observed
in the sensitivity analysis. In the MICE, similar HRs for different
study events were observed to those from the CCA. When
comparing the two analyses for different adjusted models, we
observed that HRs for the different events in the MICE analysis
were going in the same direction as the CC analysis.

Discussion
The results of our analysis with data collected from primary
healthcare centers in Catalonia show a positive association
between the DR and major cardiovascular events (CHD and
stroke) and all-cause mortality.
Coronary heart disease, stroke, and DR have common
risk factors, such as hyperglycemia, hyperlipidemia, and
hypertension. Several studies have observed an association
between DR and macrovascular disease and subclinical
atherosclerosis (10–14). Some studies have reported that DR
is a strong determinant of carotid intima-media thickness
and arterial stiffness in patients with T2DM (12, 13). In the
Atherosclerosis Risk in Communities (ARIC) cohort study
based on a population of 1,524 people with T2DM without

FIGURE 2

Survival curves and different study events and stages of diabetic retinopathy. (A1) All-cause mortality; (B1) coronary heart disease; (C1) stroke;
(D1) macrovascular complications; (A2) all-cause mortality and different states of DR; (B2) coronary heart disease and different states of DR;
(C2) stroke and different states of DR; (D2) and different states of DR and different states of DR.
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TABLE 3 Hazard ratios for events among the study groups complete cases analysis.

General

Stage of DR

Diabetic macular
Group
Group with Non-proliferative
Proliferative
edema (DME)
without DR
DR
diabetic retinopathy
diabetic
N = 475
N = 196,983 N = 22,402 (NPDR) N = 19,048 retinopathy (PRD)
N = 663

Unknown stage*
N = 2,216

17,527 (8.90)

3,364 (15.0)

2,794 (14.7)

144 (21.7)

76 (16.0)

350 (15.8)

Unadjusted HR 95% CI
[LL; UL]

Ref.

1.75 [1.69;1.82]

1.69 [1.62;1.76]

2.82 [2.39;3.32]

2.44 [1.95;3.06]

1.91 [1.72;2.12]

**Adjusted HR 95% CI
[LL; UL]

Ref.

1.34 [1.28;1.41]

1.34 [1.27;1.42]

1.68 [1.31;2.15]

1.71 [1.27;2.31]

1.19 [1.03;1.38]

***Adjusted HR 95% CI
[LL; UL]

Ref.

1.34 [1.27;1.41]

1.34 [1.26;1.41]

1.66 [1.30;2.13]

1.69 [1.25;2.28]

1.19 [1.03;1.38]

Mortality, n (%)

6,360 (3.23)

1,058 (4.72)

904 (4.75)

38 (5.73)

22 (4.63)

94 (4.24)

Unadjusted HR 95% CI
[LL; UL]

Ref.

1.84 [1.70;1.99]

1.51 [1.41;1.62]

2.00 [1.45;2.75]

1.82 [1.20;2.76]

1.39 [1.13; 1.70]

**Adjusted HR 95% CI
[LL; UL]

Ref.

1.27 [1.16;1.39]

1.30 [1.19;1.43]

1.17 [0.71;1.92]

0.80 [0.38; 1.68]

1.11[0.86;1.44]

***Adjusted HR 95% CI
[LL; UL]

Ref.

1.28 [1.17;1.40]

1.31 [1.19;1.44]

1.18 [0.72;1.92]

0.81 [0.38; 1.69]

1.11[0.86;1.44]

CHD, n (%)

3,637 (1.85)

563 (2.51)

468 (2.46)

26 (3.92)

9 (1.89)

60 (2.71)

Unadjusted HR 95% CI
[LL; UL]

Ref.

1.75 [1.64;1.86]

1.36 [1.24;1.50]

2.41 [1.64;3.55]

1.30 [0,68;2.50]

1.56 [1.20;2.01]

**Adjusted HR 95% CI
[LL; UL]

Ref.

1.09 [0.97;1.24]

1.11 [0.97;1.26]

1.65[0.95;2.86]

0.74 [0.27;1.99]

0.93[0.65;1.33]

***Adjusted HR 95% CI
[LL; UL]

Ref.

1.09 [0,97;1,24]

1.11 [0.97;1.26]

1.65[0.95;2.85]

0.74 [0.28;1.98]

0.93[0.65;1.33]

Stroke, n (%)

9,758 (4.95)

1,584 (7.07)

1,341 (7.04)

61 (9.02)

30 (6.32)

152 (6.86)

Unadjusted HR 95% CI
[LL; UL]

Ref.

1.75 [1.64; 1.86]

1.47 [1.39; 1.55]

2.12 [1.65; 2.73]

1.62 [1.13; 2.31]

1.48 [1.26; 1.73]

**Adjusted HR 95% CI
[LL; UL]

Ref.

1.22 [1.13; 1.31]

1.24 [1.15;1.34]

1.29 [0.88; 1.89]

0.79 [0.44; 1.44]

1.08 [0.87;1.33]

***Adjusted HR 95% CI
[LL; UL]

Ref.

1.22 [1.14; 1.31]

1.25 [1.15;1.35]

1.30 [0.89; 1.90]

0.80 [0.44; 1.44]

1.08 [0.88;1.33]

Macrovascular, n (%)

DR, diabetic retinopathy; CHD, coronary heart disease; NDR, no apparent diabetic retinopathy; NPDR, non-proliferative diabetic retinopathy; PDR, proliferative diabetic retinopathy;
DME, diabetic macular edema; ref, reference group; HR, hazard ratio; 95% CI, 95% confidence interval; LL, lower limit; UL, upper limit.
*Subjects having diabetic retinopathy by diagnostic code but without fundus photography/stage of DR.
**Adjusted for DR, sex, age, BMI, tobacco, duration of T2DM, an antiplatelet or antihypertensive drug, and HbA1c.
***Adjusted for DR, sex, age, BMI, tobacco, duration of T2DM, an antiplatelet, antihypertensive, lipid-lowering, or antidiabetic drugs, and HbA1c.

DR was associated with an increased risk of stroke (HR:
1.25, 95% CI: 1.12; 1.39). Subgroup analysis for the type
of diabetes yielded a pooled HR of 1.29 and 95% CI:
1.10; 1.50 in T2DM (21). In a secondary analysis of
patients enrolled in the Action to Control Cardiovascular
Risk in Diabetes (ACCORD) Eye Study in an adjusted Cox
regression model, DR was independently associated with
incident stroke (HR:1.52, 95% CI:1.05; 2.20) (22). Another
prospective cohort study with 1,617 middle-aged people with
diabetes observed that during a follow-up of 7.8 years, DR
was associated with an increased risk of ischemic stroke
(HR: 2.34, 95% CI: 1.13; 4.86) (24). In our study, we did
not observe associations between DR or stage of DR and
stroke in fully adjusted models, which could be due to the

Frontiers in Medicine

methodological differences or diagnostic codes used to identify
the cases with stroke.
Regarding all-cause mortality, our study shows that the
presence of any degree of DR is correlated with an increased
risk of this event. In a study from the United States with
4,777 adults, the authors found that those persons with mild
and moderate/severe retinopathy had an increased risk of allcause mortality (HR: 1.81, 95% CI: 1.29; 2.55 and HR: 4.14,
95% CI: 1.77; 9.69, respectively) (30). In another meta-analysis
from ten observational studies with 11,239 diabetic patients,
the authors reported a doubling in the risk of mortality due
to CVD in subjects with diabetes and severe DR (31). Similar
results were also obtained in the analysis of other studies
with similar follow-up periods in a meta-analysis of 19 studies
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FIGURE 3

Hazard ratios for cardiovascular events and mortality according retinopathy Sensitivity analysis. M1, unadjusted; M2, sex, age; M3, sex, smoking,
diabetes, antiaggregants, antihypertensive, BMI; M4, sex, age, smoking, diabetes, duration, antiaggregants, antihypertensive, HBA1C, BMI; M5,
age, smoking, diabetes, duration, antiaggregants, antihypertensive, antidiabetes, libid-lowering drugs, HBA1C, BMI.

to define each study event. Another limitation is the numerical
imbalance between the different groups due to the study design
and lack of randomization. Moreover, we should acknowledge
there is an inherent possibility of a certain risk of detection bias
related to the frequency of medical visits. To minimize this bias,
we designed the study to include only DM subjects who had
at least one visit. We included the subjects in the study on the
day of diabetic eye screening. Therefore, all the subjects were
active users of the system. The main strength of our study was
the large study population which increases the statistical power
and external validity. Similarly, the results of our study confirm
the results of previous studies.
In conclusion, our results show that DR is associated with
an increased risk of cardiovascular disease and death among
persons with T2DM. These findings indicate the importance of
early screening, identification, and proper treatment of subjects
with DR to reduce the risk of macrovascular disease and death.
Further functional studies are needed to evaluate the biological
background of these complications of diabetes and the potential
use of stages of DR as an early marker for major adverse
cardiovascular events.

encompassing 142,625 participants; the risk ratio (RR) for allcause mortality with DR was 2.33 (95% CI: 1.92; 2.81) compared
to subjects without DR. According to the different degrees
of DR in subjects with T2DM, the RR of all-cause mortality
varied. The RDNP risk was 1.38 (1.11–1.70), while the risk of
PDR was 2.32 (1.75; 3.06) (32). Our analysis only observed
statistically significant risks for all-cause mortality stratified
for different stages of DR; this risk was highest among the
persons who had PDR.
Our study has some potential limitations inherent in
observational studies with routinely collected healthcare data.
Firstly, missing data for the study variables is an important
limitation. We used pseudo-anonymized routinely collected
health data, where patients were visited as part of the regular
healthcare surveillance. To test the effect of this limitation, we
did a CCA and multiple imputations of missing data, and the
results were consistent. Due to the database characteristics, there
is a possibility of registering errors related to the diagnostic code
for DR. Therefore, we used the fundus photography results and
combined them with diagnostic codes. This limitation could also
be applied to the study events. We used a wide spectrum of codes
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